{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/","result":{"pageContext":{"chapter":{"id":"ccf35d76-5a70-5707-9d61-52ca23e54e91","slug":"immunizations-seasonal-influenza","fullItemName":"Scenario: Immunizations - seasonal influenza","depth":2,"htmlHeader":"<!-- begin field 68ad41cd-2958-476a-a9c7-a0d04af39f88 --><h2>Scenario: Immunizations - seasonal influenza</h2><!-- end field 68ad41cd-2958-476a-a9c7-a0d04af39f88 -->","summary":"Covers the immunization of people with influenza vaccine in primary care, in line with the national seasonal influenza immunization programme.","htmlStringContent":"<!-- begin item dfe1e60d-f895-4a31-ab26-97ef8128fdbd --><!-- begin field 6aacadc8-520e-4983-a988-acd900ab33cf --><p>From age 6 months onwards.</p><!-- end field 6aacadc8-520e-4983-a988-acd900ab33cf --><!-- end item dfe1e60d-f895-4a31-ab26-97ef8128fdbd -->","topic":{"id":"9b6b800a-723f-5d15-a3b3-e02063fe3c99","topicId":"92586dea-3104-4e8a-bc44-03b987a2edbd","topicName":"Immunizations - seasonal influenza","slug":"immunizations-seasonal-influenza","lastRevised":"Last revised in December 2020","chapters":[{"id":"d76923a5-5c5f-5a11-a814-a5cb25677ea4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2ba8fbd2-e67d-5358-81f0-924960cf0be5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"732d4482-9024-5590-a7eb-2302afbfdfb4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"01093f11-51ae-50df-8509-ec07849034a9","slug":"changes","fullItemName":"Changes"},{"id":"acbbda46-e0ae-5671-bacb-2a6a13a3c48c","slug":"update","fullItemName":"Update"}]},{"id":"2076ad4b-733a-531b-a566-ab63793ca4c5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"abdfa463-1f9a-5c6c-97e5-0c8cf32a1245","slug":"goals","fullItemName":"Goals"},{"id":"8771bc09-4770-5b11-9629-ba462c397ae6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cabc3c03-ff36-515a-b973-f91f2f073567","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7a42bc64-dd67-5232-9220-bdf56acb5c4c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6334087f-5e9d-5ae0-b123-0988f7171dc7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b60207bc-ceae-5d6f-abb8-1f6bc080bffc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4c8ddd5f-4fd9-5971-b539-806fa0341ca6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2ecf8cae-934e-53ec-8216-de939261798a","slug":"definition-of-influenza","fullItemName":"Definition of influenza"},{"id":"1340565d-3167-5013-892b-f55f963e594b","slug":"influenza-vaccines","fullItemName":"Influenza vaccines"}]},{"id":"c24a89e0-d8d7-53a8-b2d4-4187af763e27","fullItemName":"Management","slug":"management","subChapters":[{"id":"ccf35d76-5a70-5707-9d61-52ca23e54e91","slug":"immunizations-seasonal-influenza","fullItemName":"Scenario: Immunizations - seasonal influenza"}]},{"id":"768b3628-e7db-58a1-8684-aead55533454","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d99a53cc-c2a9-507d-b699-09ee1f7cc101","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"863e5e76-1aca-5995-a6e9-d1a5fb5014a9","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0f50bd98-0307-58c8-a950-f50210eac7fa","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"203d2edb-0764-5bf9-b609-e73840389249","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c5ecb68c-3006-54b8-8490-50ca223f01c9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a537af28-d7fb-50c5-8510-d92fbf917777","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"195ebe32-2726-5fb9-a629-dd9e743c180b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c24a89e0-d8d7-53a8-b2d4-4187af763e27","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"be914a93-bee7-56ab-b0a6-4acdbc498d56","slug":"who-to-immunize","fullItemName":"Who to immunize","depth":3,"htmlHeader":"<!-- begin field 06bb2d14-3428-4328-9658-cac6c2b8d32d --><h3>Who should be offered the seasonal influenza immunization?</h3><!-- end field 06bb2d14-3428-4328-9658-cac6c2b8d32d -->","summary":null,"htmlStringContent":"<!-- begin item 6bde559f-71e8-4d7f-9830-0219014e683c --><!-- begin field e32f04d8-707d-4412-8ce3-19f447815c55 --><ul><li><strong>Note:</strong> influenza vaccination should be given as soon as possible to provide protection before flu starts to circulate and should ideally be completed by the end of November, but can also take place up until the following 31 March.</li><li><strong>Annual seasonal influenza immunization is recommended for people in the following groups who are more at risk of the complications of influenza, including:</strong><ul><li>All people aged 65 years and older, and for 2020-21 people aged 50-64 years (subject to vaccine supply).</li><li>All people aged 6 months to under 65 years in clinical risk groups (see Table 1):</li></ul></li></ul><p><strong>Table 1.</strong> Clinical risk groups in people aged 6 months and older</p><table data-table-id=\"1ce6d1f4-dac6-483c-97ae-acce014ee6a0\"><thead><tr><th colspan=\"1\">Clinical risk group</th><th colspan=\"1\">Representative examples</th></tr></thead><tbody><tr><td colspan=\"1\">Chronic respiratory disease</td><td colspan=\"1\">Including people with chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis, and bronchopulmonary dysplasia (BPD). People with asthma which is so severe that it requires continuous or repeated use of inhaled or systemic corticosteroids, or with previous exacerbations requiring hospital admission. Children who have previously been admitted to hospital for lower respiratory tract disease.</td></tr><tr><td colspan=\"1\">Chronic heart disease</td><td colspan=\"1\">Including people with congenital heart disease, hypertension with cardiac complications, chronic heart failure, and people requiring regular medication or follow up for ischaemic heart disease.</td></tr><tr><td colspan=\"1\">Chronic kidney disease</td><td colspan=\"1\">Including people with chronic kidney disease stage 3, 4 or 5, nephrotic syndrome, and renal transplantation.</td></tr><tr><td colspan=\"1\">Chronic liver disease</td><td colspan=\"1\">Including people with cirrhosis, biliary atresia, and chronic hepatitis.</td></tr><tr><td colspan=\"1\">Chronic neurological disease</td><td colspan=\"1\">Including people with stroke and transient ischaemic attack (TIA). People with co-morbidities that could be exacerbated by influenza, or who are at risk of serious illness from influenza itself, depending on clinical judgement, for example, people with cerebral palsy, learning disabilities, Parkinson's disease, multiple sclerosis, motor neurone disease, or hereditary and degenerative diseases of the central nervous system or muscles, or severe neurological disability. Conditions where respiratory function may be compromised, such as people with polio syndrome.</td></tr><tr><td colspan=\"1\">Diabetes mellitus</td><td colspan=\"1\">Including people with type 1 diabetes; and type 2 diabetes that is diet-controlled, requires oral anti-diabetic drugs, or insulin.</td></tr><tr><td colspan=\"1\">Immunosuppression</td><td colspan=\"1\">Due to disease or treatment, and includes people undergoing chemotherapy; bone marrow transplant; multiple myeloma; people with HIV/AIDS; genetic disorders affecting the immune system (for example complement deficiencies); people on DMARDs or biologics for rheumatoid disease, people treated with, or likely to be treated with, systemic corticosteroids for more than a month at dosages equivalent to prednisolone 20 mg or more daily (any age), or for children who weigh less than 20 kg, a dose of 1 mg or more per kg per day. <strong>Note:</strong> some immunocompromised people may have a suboptimal immunological response to the seasonal influenza vaccine.</td></tr><tr><td colspan=\"1\">Asplenia or splenic dysfunction</td><td colspan=\"1\">Including people with homozygous sickle cell disease and coeliac disease.</td></tr><tr><td colspan=\"1\">Pregnant women*</td><td colspan=\"1\">At any stage of pregnancy, including women who become pregnant later in the influenza season.</td></tr><tr><td colspan=\"1\">Morbid obesity</td><td colspan=\"1\">Adults with a body mass index (BMI) of 40 kg per m<sup>2</sup> or greater, depending on clinical judgement.</td></tr><tr><td colspan=\"2\">*Use clinical judgement to assess whether influenza vaccine should be offered to newly pregnant women, particularly if after the usual immunization time period, taking into account the level of influenza-like illness in the community, and the fact that the immune response following immunization takes about two weeks to fully develop. <strong>Note:</strong> this list is not exhaustive and any person with a medical condition or disease that may be exacerbated by influenza infection, or who may be at risk of serious illness from influenza infection, should be offered influenza immunization, including those on the COVID-19 shielded group and depending on clinical judgement.</td></tr><tr><td colspan=\"2\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>]</td></tr></tbody></table><ul><li><strong>Seasonal influenza immunization is recommended in certain healthy people to reduce the risk of transmission to vulnerable groups, including:</strong><br><ul><li>Children aged 2 to 10 years on 31 August 2020, and for 2020-21 children of school year 7 age in secondary schools (those aged 11 years on 31 August 2020).</li><li>People living in long-stay residential and nursing homes or other long-stay care facilities (not including prisons, young offender's institutions, or university halls of residence).</li><li>Close contacts of immunocompromised people, including carers (people who expect to share living accommodation on most days over the winter).</li><li>All healthcare and social care workers directly involved in patient care, including students, trainees, and volunteers working with patients.<ul><li>This should be provided by their employer's occupational health service unless the person falls within one of the clinical risk groups (see Table 1).</li></ul></li><li>People in receipt of a carer's allowance, or those who are the main carer of an elderly or disabled person<strong> </strong>whose welfare may be at risk if the carer falls ill. This should be considered on an individual basis, at the healthcare professional's discretion.</li><li>Hajj and Umrah pilgrims.<ul><li>The Ministry of Health for the Kingdom of Saudi Arabia recommends that international pilgrims are immunized against influenza before they enter Saudi Arabia, especially travellers in at risk groups. For travellers not in at risk groups, seasonal influenza vaccination is not available on the NHS and must be paid for, for example at some GP surgery travel clinics, pharmacies, or private travel clinics.</li></ul></li></ul></li><li><strong>In addition, for 2020/21, seasonal flu vaccination will also be offered to:</strong><ul><li>Household contacts of those on the NHS Shielded Patient List. Specifically, individuals who expect to share living accommodation with a shielded person on most days over the winter and therefore for whom continuing close contact is unavoidable.</li><li>Health and social care workers employed through Direct Payment (personal budgets) and/or Personal Health Budgets, such as personal assistants, to deliver domiciliary care to patients and service users. </li></ul></li></ul><!-- end field e32f04d8-707d-4412-8ce3-19f447815c55 --><!-- end item 6bde559f-71e8-4d7f-9830-0219014e683c -->","subChapters":[{"id":"40d81171-0e21-50bf-8117-13c08995e477","slug":"basis-for-recommendation-c3b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f85bb9b4-b730-4b00-af76-20e2c3d2f5c7 --><h4>Basis for recommendation</h4><!-- end field f85bb9b4-b730-4b00-af76-20e2c3d2f5c7 -->","summary":null,"htmlStringContent":"<!-- begin item c3b8e5bc-e154-4a53-b640-e67f39ac4a7d --><!-- begin field e327dc1b-15a9-465d-816d-513bb35e2e30 --><p>The recommendations are based on the chapter <em>Influenza</em> in the Public Health England (PHE) document <em>Immunisation against infectious disease (the 'Green Book</em>') [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>], the NHS England letter <em>The national flu immunisation programme 2020 to 2021 - update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">NHS England, 2020</a>], and the National Travel Health Network and Centre (NaTHNaC) factsheet <em>Hajj and Umrah</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">NaTHNaC, 2019</a>]. </p><!-- end field e327dc1b-15a9-465d-816d-513bb35e2e30 --><!-- end item c3b8e5bc-e154-4a53-b640-e67f39ac4a7d -->","subChapters":[]}]},{"id":"6023b1f2-807f-5cdc-aee3-b5e392bd8123","slug":"influenza-vaccines-available","fullItemName":"Influenza vaccines available","depth":3,"htmlHeader":"<!-- begin field 28e5c909-7a2e-40b9-a941-f75cd59d18f8 --><h3>Which influenza vaccines are available?</h3><!-- end field 28e5c909-7a2e-40b9-a941-f75cd59d18f8 -->","summary":null,"htmlStringContent":"<!-- begin item 6f405b41-b373-4879-a688-71f9fc63a70a --><!-- begin field 8d55be20-0046-4cc8-bed0-246ecbe8ba01 --><ul><li><strong>See Table 2 for a list of influenza vaccines available for the 2020/2021 influenza season. </strong>For more detailed information about individual influenza vaccines, see the manufacturers' Summary of Product Characteristics on the <a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"70d100b3-0a00-4aba-851d-a8f7014f894b\">electronic Medicines Compendium</a> website. <ul><li>None of the vaccines listed contain thiomersal as an added preservative. Most of the viruses are grown in embryonated hens' eggs and are then chemically inactivated before being further treated and purified.</li><li>Quadrivalent vaccines contain two subtypes of influenza A virus and two subtypes of influenza B virus.</li><li>In the 2020-2021 influenza season in the northern hemisphere, it is recommended that egg-based quadrivalent vaccines include: <ul><li>An A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus.</li><li>An A/Hong Kong/2671/2019 (H3N2)-like virus.</li><li>A B/Washington/02/2019 (B/Victoria lineage)-like virus. </li><li>A B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.</li></ul></li><li>In the 2020-2021 influenza season in the northern hemisphere, it is recommended that cell- or recombinant-based quadrivalent vaccines include: <ul><li>An A/Hawaii/70/2019 (H1N1)pdm09-like virus.</li><li>An A/Hong Kong/45/2019 (H3N2)-like virus.</li><li>A B/Washington/02/2019 (B/Victoria lineage)-like virus. </li><li>A B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.</li></ul></li></ul></li><li><strong>In the 2020-2021 influenza season, it is recommended that:</strong><ul><li><strong>All people aged 65 years and older</strong> should receive the adjuvanted trivalent inactivated vaccine (aTIV). <ul><li>The cell-based quadrivalent influenza vaccine (QIVc) (Flucelvax Tetra) can be offered if aTIV is unavailable.</li></ul></li><li><strong>At risk adults aged 18 to 64 years </strong>(including pregnant women, healthcare workers, and carers) should receive a quadrivalent inactivated vaccine (QIVc), or recombinant quadrivalent vaccine (QIVr), or if these are not available, the egg-grown quadrivalent influenza vaccine (QIVe). </li><li><strong>Healthy adults aged 50 to 64 years</strong> (not in a risk group from 1 December 2020) should receive a quadrivalent inactivated vaccine (QIVc), or recombinant quadrivalent vaccine (QIVr), or if these are not available, the egg-grown quadrivalent influenza vaccine (QIVe). </li><li><strong>Children aged 2 to 17 years in a </strong><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#who-to-immunize\">clinical risk group</a><strong>, or as part of the national influenza immunisation programme</strong>, should receive the quadrivalent live attenuated influenza vaccine (LAIV) given as a nasal spray (Fluenz Tetra).<ul><li>Children in clinical risk groups, or who are household contacts of those on the NHS shielded patients list or of immunocompromised people who have never previously received influenza vaccine, and are aged less than nine years should be offered a second dose of Fluenz Tetra<sup> </sup>at least 4 weeks later. If Fluenz Tetra is unavailable for this second dose (due to batch expiry) an inactivated influenza vaccine can be given (see product inserts for advice about use in specific age groups). </li><li>Children aged under 9 years who are contraindicated to LAIV should be offered a QIVe.</li><li>Children aged 9 years and over who are contraindicated to LAIV should be offered QIVc.</li><li>Note: Fluenz Tetra contains a highly-processed form of porcine gelatine which may not be acceptable to some faith groups. Children and young people in a <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#who-to-immunize\">clinical risk group</a> who choose not to have, the nasal spray should be offered a QIVe. For 2020/21, children who are not in a clinical risk group may be offered an alternative vaccine (providers will receive notification of a suitable alternative). </li></ul></li><li><strong>For children in clinical risk groups aged from 6 months to less than 2 years </strong>offer a suitable QIVe. Children who have not received influenza vaccine previously should be offered a second dose at least 4 weeks later. <ul><li>Note: inactivated influenza vaccines can be considered interchangeable for children younger than 9 years of age who require a second dose of influenza vaccine (but see product inserts for advice about use in specific age groups). See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#administering-influenza-vaccines\">administering influenza vaccines</a> for more information. </li></ul></li></ul></li></ul><p><strong>Table 2.</strong> Influenza vaccines available for the 2020/2021 influenza season.</p><table data-table-id=\"51c08445-35c3-43ce-9ae2-acce014eec83\"><thead><tr><th scope=\"col\"><strong>Supplier</strong></th><th scope=\"col\"><strong>Name of product</strong></th><th scope=\"col\"><strong>Vaccine type</strong></th><th scope=\"col\"><strong>Additional information</strong></th><th scope=\"col\"><strong>Ovalbumin content</strong></th><th scope=\"col\"><strong>Age of indications</strong></th></tr></thead><tbody><tr><td>AstraZeneca </td><td>Fluenz Tetra </td><td>LAIV</td><td>Live attenuated, nasal</td><td>Less than 0.024 micrograms per 0.2 ml dose</td><td>From 2 years to less than 18 years</td></tr><tr><td>GSK</td><td>Fluarix Tetra </td><td>QIVe</td><td>Split virion, inactivated virus </td><td>Equal to or less than 0.05 micrograms per 0.5 ml dose</td><td>From 6 months</td></tr><tr><td>MASTA</td><td>Quadrivalent Influenza Vaccine (black triangle)</td><td>QIVe</td><td>Split viron, inactivated virus</td><td>Equal to or less than 0.05 micrograms per 0.5 ml dose</td><td>From 6 months</td></tr><tr><td>Sanofi Pasteur </td><td>Quadrivalent Influenza Vaccine (black triangle)</td><td>QIVe</td><td>Split virion, inactivated virus</td><td>Equal to or less than 0.05 micrograms per 0.5 ml dose</td><td>From 6 months</td></tr><tr><td>Mylan </td><td>Quadrivalent Influvac subunit Tetra (black triangle)</td><td>QIVe</td><td>Surface antigen, inactivated virus</td><td>Equal to or less than 0.1 micrograms per 0.5 ml dose</td><td>From 3 years</td></tr><tr><td>Seqirus</td><td>Flucelvax Tetra (black triangle)</td><td>QIVc</td><td>Surface antigen, inactivated virus, prepared in cell cultures.</td><td>Egg-free</td><td>From 9 years</td></tr><tr><td>Seqirus</td><td>Adjuvanted Trivalent Influenza Vaccine</td><td>aTIV</td><td>Surface antigen, inactivated virus, adjuvanted with MF59C.1. </td><td>Equal to or less than 0.2 micrograms per 0.5 ml dose</td><td>From 65 years</td></tr><tr><td>Sanofi Pasteur</td><td>Trivalent Influenza Vaccine High Dose* (black triangle)</td><td>TIV-HD</td><td>Split virion, inactivated virus</td><td>Equal to or less than 0.1 micrograms per 0.5 ml dose</td><td>From 65 years</td></tr><tr><td>Sanofi Pasteur</td><td>Flublok Quadrivalent**</td><td>QIVr</td><td>Recombinant influenza vaccine, quadrivalent, inactivated</td><td>Egg-free</td><td>From 18 years</td></tr><tr><td colspan=\"6\"><p>*= not a recommended vaccine for 2020-2021. <strong>Information from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2020a</a>]</p><p>**= this vaccine is licensed by the US FDA and has been authorized by the MHRA for temporary supply in the UK to meet public health need, for use in the National Immunization Programme [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2020b</a>].</p></td></tr></tbody></table><!-- end field 8d55be20-0046-4cc8-bed0-246ecbe8ba01 --><!-- end item 6f405b41-b373-4879-a688-71f9fc63a70a -->","subChapters":[{"id":"32b0643a-2037-5dd8-a305-84d928ed3d3c","slug":"basis-for-recommendation-b1d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d4579a58-1c5c-45b7-b4a7-fa7f68760403 --><h4>Basis for recommendation</h4><!-- end field d4579a58-1c5c-45b7-b4a7-fa7f68760403 -->","summary":null,"htmlStringContent":"<!-- begin item b1d9b77f-9a5d-4124-8b48-a612acd46878 --><!-- begin field e6cac3cb-f2ea-4025-9a39-86e4a1ca5bac --><p>The information is based on the chapter <em>Influenza</em> in the Public Health England (PHE) document <em>Immunisation against infectious disease (the 'Green Book</em>') [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>], the NHS England letter <em>The national flu immunisation programme 2020 to 21 - update </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">NHS England, 2020</a>], the World Health Organization (WHO) <em>Recommended composition of influenza virus vaccines for use in the 2020- 2021 northern hemisphere influenza season</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">WHO, 2020</a>].</p><!-- end field e6cac3cb-f2ea-4025-9a39-86e4a1ca5bac --><!-- end item b1d9b77f-9a5d-4124-8b48-a612acd46878 -->","subChapters":[]}]},{"id":"d9c68918-7a3b-5544-9b2d-30047b9b451e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field da0801ef-d659-4646-8570-e140a050cde9 --><h3>What contraindications and cautions are associated with influenza vaccines?</h3><!-- end field da0801ef-d659-4646-8570-e140a050cde9 -->","summary":null,"htmlStringContent":"<!-- begin item 18ec711a-08c6-4c46-9459-714df1a29db3 --><!-- begin field fd5e19d8-8e7b-4519-9b39-4ed7c776f4f3 --><ul><li><strong>Do not give influenza vaccine to people with a confirmed anaphylactic reaction to: </strong><ul><li>A previous dose of the vaccine, <em>or</em></li><li>Any component of the vaccine (except ovalbumin — see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#management-of-egg-allergy\">How should I manage a person with egg allergy?</a> for more information).<ul><li>If there is any uncertainty about the appropriate management of a person with a suspected or confirmed history of anaphylaxis, seek specialist advice from the local immunization co-ordinator, Consultant in Communicable Disease Control, or a Consultant Paediatrician, to minimize the time period that the person is left unvaccinated.</li><li>For more information on the diagnosis of anaphylaxis, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li></ul></li></ul></li><li><strong>For people with a suspected or confirmed anaphylactic reaction to one or more excipients:</strong><ul><li>Ensure that the vaccine formulation used is free of the identified excipients (for example, neomycin or other aminoglycosides). For further information, see the manufacturers' Summary of Product Characteristics for the individual influenza vaccines on the <a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"fbec1473-98a4-4192-985c-a8f7014d019a\">electronic Medicines Compendium</a> website.</li></ul></li><li><strong>For people who are allergic to egg or have had a confirmed anaphylactic reaction to egg,</strong> see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#management-of-egg-allergy\">How should I manage a person with egg allergy?</a></li><li><strong>Do not give the influenza immunization to people who are acutely unwell</strong> (with a febrile illness or acute infection) — postpone immunization until they have fully recovered.<ul><li>Note: minor illnesses without fever or systemic upset are not valid reasons to postpone immunization. </li></ul></li><li><strong>Fluenz Tetra<sup> </sup>nasal spray is contraindicated in children or young people who:</strong><ul><li>Are severely immunocompromised due to an underlying medical condition or treatment, such as leukaemia, lymphoma, and HIV infection not on treatment, an immune deficiency, are receiving (or have received in the past 3 months) high-dose corticosteroids (prednisolone at least 2 mg/kg/day for a week or 1 mg/kg/day for a month or equivalent). </li><li>Have severe asthma or active wheezing. For more information on classifying the severity of asthma, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/asthma/\">Asthma</a>. </li><li>Have a history of severe anaphylaxis to egg which has previously required intensive care management in hospital. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#management-of-egg-allergy\">How should I manage a person with egg allergy?</a> </li><li>Are taking systemic salicylate therapy. </li><li>Are pregnant or breastfeeding. </li></ul></li><li><strong>Fluenz Tetra nasal spray is not recommended in children or young people:</strong><ul><li>Who have heavy nasal congestion — consider postponing until symptoms have resolved (or using an <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#influenza-vaccines-available\">alternative vaccine</a> by an alternative route). </li><li>With a history of active wheezing in the previous 72 hours, or who have increased their bronchodilator use in the previous 72 hours — if their condition has not improved after a further 72 hours, offer an <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#influenza-vaccines-available\">alternative inactivated influenza vaccine</a>. </li><li>Where close contact with a severely immunocompromised person is likely or unavoidable (for example a person with a bone marrow transplant requiring isolation is a household contact) — consider offering an <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#influenza-vaccines-available\">alternative inactivated influenza vaccine</a>.</li><li>Until 48 hours after stopping treatment with an influenza antiviral agent. For more information on antiviral agents, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/influenza-seasonal/\">Influenza - seasonal</a>. </li></ul></li></ul><!-- end field fd5e19d8-8e7b-4519-9b39-4ed7c776f4f3 --><!-- end item 18ec711a-08c6-4c46-9459-714df1a29db3 -->","subChapters":[{"id":"0a1c09d1-a6e6-57ca-99e9-b23a3b639aa5","slug":"basis-for-recommendation-375","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b87a3d21-a94f-42c8-b689-4e892bf89b52 --><h4>Basis for recommendation</h4><!-- end field b87a3d21-a94f-42c8-b689-4e892bf89b52 -->","summary":null,"htmlStringContent":"<!-- begin item 375ac2c4-9c3a-4cbc-b66d-58f4d462b1cf --><!-- begin field a5468cdf-c459-46b3-aa00-fc34a261f761 --><p>These recommendations are based on the Public Health England (PHE) chapters on <em>Influenza</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>] and <em>Contraindications and special considerations</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2017</a>] in <em>Immunisation against infectious disease (the 'Green Book' ),</em> the PHE guidance <em>The national childhood flu immunisation programme 2019/20: information for healthcare practitioners</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019b</a>], and the manufacturers' Summary of Product Characteristics for the influenza vaccines, available on the <a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"aa8dc2c9-0f3e-4130-87c0-a8f701501b58\">electronic Medicines Compendium</a> website.</p><h5>Contraindications for live attenuated influenza vaccine (LAIV), Fluenz Tetra nasal spray</h5><ul><li>Fluenz Tetra<sup> </sup>is not recommended for children with active wheezing or known severe asthma as there are limited safety data in these patient groups.<ul><li>There are limited safety data in children who require regular oral steroids for maintenance of asthma control, or have previously required intensive care for asthma exacerbation – such children should only be given LAIV on the advice of their specialist. As these children may be at higher risk from influenza infection, those who cannot receive LAIV should receive a suitable inactivated influenza vaccine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>].</li></ul></li><li>The recommendations on people who are immunosuppressed are based on the fact that it is a live attenuated vaccine. Live vaccines can, in some situations, cause severe or fatal infections in immunosuppressed individuals due to extensive replication of the vaccine strains.</li><li>The recommendation on people taking systemic salicylate therapy is based on the risk of association of Reye's syndrome with salicylates and wild-type influenza infection.</li><li>The recommendation on not using Fluenz Tetra in pregnancy or breastfeeding is based on limited data on its safety in pregnant women, and uncertainty as to whether Fluenz Tetra is excreted in human milk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">ABPI, 2020</a>].</li></ul><h5>Oral corticosteroids and LAIV</h5><ul><li>The 'Green Book' advises that live vaccines should not be administered to people who are receiving immunosuppressive therapy or have received it in the past 3 months, including [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2017</a>]: <ul><li>High-dose corticosteroids (>40 mg prednisolone per day or 2 mg/ kg/day in children under 20 kg) for more than 1 week.</li><li>Lower dose corticosteroids (>20 mg prednisolone per day or 1 mg/kg/day in children under 20 kg) for more than 14 days.</li></ul></li><li>PHE guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019b</a>] on childhood immunization does not specify that administration of LAIV is contraindicated in children who have taken steroids in the past 3 months, but advises referring to the 'Green Book' chapter on <em>Contraindications and special considerations </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2017</a>] for further advice, while the chapter on <em>Influenza </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>] advises that it is not contraindicated for use in children or adolescents with stable HIV infection receiving antiretroviral therapy; or who are receiving topical corticosteroids, inhaled corticosteroids or low-dose systemic corticosteroids.</li><li>The Summary of Product Characteristics for Fluenz Tetra also does not specify that it is contraindicated in children who have taken steroids in the past 3 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">ABPI, 2020</a>].</li></ul><h5>Inhaled corticosteroids and LAIV</h5><ul><li>The Joint Committee on Vaccination and Immunisation (JCVI) has advised that, on the basis of recent data, children with asthma on inhaled corticosteroids may safely be given LAIV, irrespective of the dose prescribed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>]. </li></ul><!-- end field a5468cdf-c459-46b3-aa00-fc34a261f761 --><!-- end item 375ac2c4-9c3a-4cbc-b66d-58f4d462b1cf -->","subChapters":[]}]},{"id":"f4863994-131f-54ce-8695-d92282f8ba8c","slug":"management-of-egg-allergy","fullItemName":"Management of egg allergy","depth":3,"htmlHeader":"<!-- begin field a4a71075-3f98-43d7-a72b-2125581104d8 --><h3>How should I manage a person with egg allergy?</h3><!-- end field a4a71075-3f98-43d7-a72b-2125581104d8 -->","summary":null,"htmlStringContent":"<!-- begin item 2da04789-013a-4386-b129-36f23c963afa --><!-- begin field fbb7c250-0fe3-495b-8bce-92fc3b37cf51 --><ul><li><strong>Determine if the person has a true egg allergy</strong> — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information. The following are <em>not </em>considered to be true egg allergy:<ul><li>A family history of a reaction to an influenza or any other vaccine.</li><li>A family history of egg allergy.</li></ul></li><li><strong>For children with a history of severe anaphylaxis to egg</strong> which has previously required intensive care management in hospital, arrange referral to a paediatric immunologist or allergy specialist for immunization in hospital.<ul><li>Fluenz Tetra nasal spray is contraindicated in anyone who has had a severe allergic reaction (for example to anaphylaxis) to egg or to egg proteins.</li></ul></li><li><strong>For all other children with a history of egg allergy:</strong><ul><li>Fluenz Tetra can be given to most children with egg allergy in any setting, including primary care.<ul><li>Egg-allergic children with asthma can receive Fluenz Tetra provided their asthma is well-controlled. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#contraindications-cautions\">contraindications and cautions</a> for more information.</li></ul></li><li>If there are clinical <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#contraindications-cautions\">contraindications</a> to Fluenz Tetra, give an inactivated influenza vaccine with a very low ovalbumin content (less than 0.06 micrograms per 0.5 mL dose), or for children aged over 9 years, use the egg-free cell-based quadrivalent influenza vaccine (QIVc). See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#influenza-vaccines-available\">available influenza vaccines</a> for details of the ovalbumin content.</li></ul></li><li><strong>For adults with:</strong><ul><li>A history of severe anaphylaxis which has previously required intensive care management in hospital, arrange referral to an immunologist or allergy specialist for assessment for in-hospital immunization.</li><li>Less severe egg allergy, give an inactivated influenza vaccine with a very low ovalbumin content (less than 0.06 micrograms per 0.5 mL dose), or use the egg-free cell-QIVc, Flucelvax Tetra. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#influenza-vaccines-available\">available influenza vaccines</a> for details of the ovalbumin content.<ul><li>People aged 65 years and over with an egg allergy should be given the QIVc Flucelvax Tetra, as the aTIV vaccine contains more than the recommended ovalbumin content for people with egg allergy.</li></ul></li></ul></li></ul><!-- end field fbb7c250-0fe3-495b-8bce-92fc3b37cf51 --><!-- end item 2da04789-013a-4386-b129-36f23c963afa -->","subChapters":[{"id":"f98c2d10-4d48-5b03-bed2-7b6f8670de6a","slug":"basis-for-recommendation-0d2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c2fbe13c-b527-4af4-bb72-8635c90b4e54 --><h4>Basis for recommendation</h4><!-- end field c2fbe13c-b527-4af4-bb72-8635c90b4e54 -->","summary":null,"htmlStringContent":"<!-- begin item 0d2c3ea8-f09f-4915-9a23-6189c7290f13 --><!-- begin field a92669b6-fd64-4262-b335-665ea6c29975 --><p>The recommendations are based on the chapter <em>Influenza </em>in the Public Health England (PHE) document <em>Immunisation against infectious disease (the 'Green Book') </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>], the PHE guidance <em>The national childhood flu immunisation programme 2019/20: information for healthcare practitioners</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019b</a>], and the Summary of Product Characteristics for Fluenz Tetra [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">ABPI, 2020</a>].</p><h5>Diagnosing egg allergy</h5><ul><li>This guidance is derived from information in a narrative review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">Erlewyn-Lajeunesse et al, 2009</a>] and the expert opinion of a previous external reviewer of this CKS topic.</li></ul><!-- end field a92669b6-fd64-4262-b335-665ea6c29975 --><!-- end item 0d2c3ea8-f09f-4915-9a23-6189c7290f13 -->","subChapters":[]}]},{"id":"4d9c9542-2cab-50c0-8a6f-842f7187d1cf","slug":"administering-influenza-vaccines","fullItemName":"Administering influenza vaccines","depth":3,"htmlHeader":"<!-- begin field 8fa95fd8-1cd8-4c90-a594-ea0173525518 --><h3>How should I administer influenza vaccines?</h3><!-- end field 8fa95fd8-1cd8-4c90-a594-ea0173525518 -->","summary":null,"htmlStringContent":"<!-- begin item 20e9f282-9a83-44f0-b701-b86b9903cb60 --><!-- begin field 1317c48f-b891-49c2-91fe-dc54805eb929 --><ul><li><strong>Seasonal influenza vaccine should be given annually, ideally between September and early November. </strong></li><li><strong>Obtain written or verbal consent at the time of vaccination for people aged over 16 years. </strong>For younger people, it is usual to get consent from a person with parental responsibility.</li><li><strong>For Fluenz Tetra intranasal spray, give a single application of 0.1 mL in each nostril. </strong>The dose does not need to be repeated if the child or young person blows their nose or sneezes after administration. </li><li><strong>Administer the other influenza vaccines by intramuscular injection </strong>(people taking anticoagulants and people with bleeding disorders may also be vaccinated intramuscularly). <ul><li>For adults and children aged 1 year and older, use the deltoid area of the upper arm or the anterolateral aspect of the thigh.</li><li>For infants younger than 1 year of age, use the anterolateral aspect of the thigh.</li><li>Do not give immunizations into the buttock area.</li><li><strong>Note: </strong>Some of the summaries of product characteristics (SPCs) for intramuscular inactivated influenza vaccines indicate that young children can be given either a 0.25ml or a 0.5ml dose. JCVI has advised that where these alternative doses are indicated, the 0.5ml dose of intramuscular inactivated influenza vaccine should be given to infants and children aged 6 months or older.</li></ul></li><li><strong>Ensure that the brand of vaccine, batch number, and administration site are accurately recorded in the person's records. </strong></li><li><strong>Influenza vaccines can be given at the same time as other live or inactivated vaccines.</strong><ul><li>Administer the vaccines at separate sites, preferably in a different limb (if appropriate).<ul><li>If the vaccines need to be given in the same limb, use vaccination sites at least 2.5 cm apart.</li></ul></li></ul></li><li><strong>If there is inadvertent administration of Fluenz Tetra to a person with a clinical <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#contraindications-cautions\">contraindication</a>:</strong><ul><li>If the person is severely immunocompromised, consider the use of influenza antiviral prophylaxis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/influenza-seasonal/\">Influenza - seasonal</a>. If antiviral prophylaxis is used, offer inactivated influenza vaccine immediately to provide ongoing protection for the current influenza season. If there is any uncertainty about management, seek specialist advice.</li><li>For all other people, advise them to seek medical advice if they develop influenza-like symptoms in the four days following administration of Fluenz Tetra. For more information on typical symptoms of influenza, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/influenza-seasonal/\">Influenza - seasonal</a>.</li></ul></li><li><strong>Be aware that very severely immunocompromised healthcare professionals should not administer Fluenz Tetra intranasal spray,</strong> due to a theoretical risk of acquiring vaccine virus due to exposure to the live attenuated vaccine.</li></ul><!-- end field 1317c48f-b891-49c2-91fe-dc54805eb929 --><!-- end item 20e9f282-9a83-44f0-b701-b86b9903cb60 -->","subChapters":[{"id":"9d2bc359-809a-5c59-8fa7-e8358f2c3cc6","slug":"basis-for-recommendation-493","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b75e9221-4769-468a-bdfb-91873d9f6bc6 --><h4>Basis for recommendation</h4><!-- end field b75e9221-4769-468a-bdfb-91873d9f6bc6 -->","summary":null,"htmlStringContent":"<!-- begin item 493b2972-4c5b-4913-bd57-8bdf172bea05 --><!-- begin field 741ea649-77df-47ea-a01b-059d9dd4cd92 --><p>The recommendations are based on the chapter <em>Influenza </em>in the Public Health England (PHE) document <em>I</em><em>mmunisation against infectious disease (the 'Green Book') </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>], the PHE guidance <em>The national childhood flu immunisation programme 2019/20: information for healthcare practitioners</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019b</a>], and the Summary of Product Characteristics for Fluenz Tetra [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">ABPI, 2020</a>].</p><p><strong>People taking anticoagulants and people with bleeding disorders </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>]</p><ul><li>There is a lack of evidence that the subcutaneous route of vaccination is any safer than the intramuscular route in people taking anticoagulants. The subcutaneous route can itself be associated with an increase in localised reactions.<ul><li>People on stable anticoagulation therapy, including individuals on warfarin who are up-to-date with their scheduled International Normalised Ratio (INR) testing and whose latest INR was below the upper threshold of their therapeutic range, can receive intramuscular vaccination. A fine needle (23 or 25 gauge) should be used for the vaccination, followed by firm pressure applied to the site (without rubbing) for at least 2 minutes. </li></ul></li><li>People with bleeding disorders may be vaccinated intramuscularly if, in the opinion of a doctor familiar with the individual's bleeding risk, vaccines or similar small volume intramuscular injections can be administered with reasonable safety by this route.<ul><li>For people receiving medication/treatment to reduce bleeding, for example treatment for haemophilia, intramuscular vaccination can be scheduled shortly after the medication/ treatment is administered. A fine needle (23 or 25 gauge) should be used for the vaccination, followed by firm pressure applied to the site (without rubbing) for at least 2 minutes. The individual/parent/carer should be informed about the risk of haematoma from the injection.</li></ul></li></ul><!-- end field 741ea649-77df-47ea-a01b-059d9dd4cd92 --><!-- end item 493b2972-4c5b-4913-bd57-8bdf172bea05 -->","subChapters":[]}]},{"id":"bef94046-c68c-59aa-a579-7e9ef83c2e09","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 31a423de-6b93-40be-b8a7-5381191a8233 --><h3>What are the adverse effects of influenza vaccines?</h3><!-- end field 31a423de-6b93-40be-b8a7-5381191a8233 -->","summary":null,"htmlStringContent":"<!-- begin item 757d0575-f619-4a9e-9d4b-89f57c7002cc --><!-- begin field ec690ed4-84e9-4244-8ab7-10bdcdf08855 --><ul><li><strong>Advise that the following adverse effects are common</strong> after influenza immunization and usually disappear within 1–2 days without needing treatment:<ul><li>Pain, swelling, or redness at the injection site.</li><li>A small painless nodule (induration) at the injection site.</li><li>Low-grade fever, malaise, shivering, or fatigue.</li><li>Headache, myalgia, or arthralgia.</li><li>Nasal congestion, rhinorrhoea, reduced appetite, and headache following administration of Fluenz Tetra<sup> </sup>nasal spray.</li></ul></li><li><strong>Be aware that rare adverse effects may include:</strong><ul><li>Neuralgia, paraesthesia, convulsions, and transient thrombocytopenia.</li><li>Vasculitis with transient renal involvement (very rare).</li><li>Neurological disorders such as encephalomyelitis and neuritis (very rare).</li></ul></li><li><strong>Report all serious suspected adverse reactions to influenza vaccines using the Yellow Card scheme</strong> (website available at <a href=\"https://yellowcard.mhra.gov.uk/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"0e309a7f-9296-4ce2-9821-a8f7014f8e96\">https://yellowcard.mhra.gov.uk</a>).<ul><li>Report <em>any</em> suspected adverse reactions to vaccines which are black triangle drugs, as they are subject to intensive surveillance by the Medicines and Healthcare products Regulatory Agency (MHRA). </li></ul></li></ul><!-- end field ec690ed4-84e9-4244-8ab7-10bdcdf08855 --><!-- end item 757d0575-f619-4a9e-9d4b-89f57c7002cc -->","subChapters":[{"id":"62ab6b68-9f41-5202-856f-f1e4fa76eb1f","slug":"basis-for-recommendation-965","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 75f112eb-473f-4af0-8872-3727d09e0968 --><h4>Basis for recommendation</h4><!-- end field 75f112eb-473f-4af0-8872-3727d09e0968 -->","summary":null,"htmlStringContent":"<!-- begin item 9653d618-f108-4e4f-b20b-296cf3a27766 --><!-- begin field 55fc0122-7701-4e09-ac6f-65c3ca9fae23 --><p>This information is based on the chapter <em>Influenza </em>in the Public Health England (PHE) document <em>Immunisation against infectious disease (the 'Green Book') </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>], and the manufacturers' Summaries of Product Characteristics (SPCs) for influenza vaccines. For more detailed information about individual influenza vaccines, see the SPCs on the <a data-hyperlink-id=\"da7b4802-04fd-46f8-8756-a8f7015c0ad4\" href=\"http://www.medicines.org.uk/\">electronic Medicines Compendium</a> website.</p><!-- end field 55fc0122-7701-4e09-ac6f-65c3ca9fae23 --><!-- end item 9653d618-f108-4e4f-b20b-296cf3a27766 -->","subChapters":[]}]},{"id":"3f7f3031-d0fb-5c70-b4f7-9fbe337f6f5b","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field 7695abdd-ec8a-44fc-9d86-a508d0ce27d5 --><h3>What information and advice should I give?</h3><!-- end field 7695abdd-ec8a-44fc-9d86-a508d0ce27d5 -->","summary":null,"htmlStringContent":"<!-- begin item 689d104f-f313-43fc-b4f3-25f1fce6c415 --><!-- begin field 398903df-baf0-4bb9-a135-76057845cbaf --><ul><li><strong>Advise the person or family/carers that:</strong><ul><li>The protection provided by the influenza vaccine lasts for about one year.</li><li>After vaccination, antibody levels may take 10–14 days to reach a protective level.</li><li>The influenza vaccine will not protect the person from other micro-organisms that can cause similar respiratory infections, such as the common cold and respiratory syncytial virus.</li><li>People who have received the Fluenz Tetra nasal spray should avoid close contact with severely immunocompromised people for 1–2 weeks following vaccination, if possible.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/management/immunizations-seasonal-influenza/#adverse-effects\">Adverse effects</a> are generally minor, and usually disappear within 1–2 days without the need for treatment.</li><li>They need to be vaccinated annually (usually before mid-November).</li></ul></li><li><strong>Provide sources of information and advice</strong> on the influenza vaccine and national influenza immunization programme, including patient information <a data-hyperlink-id=\"66d64ccf-41cd-47a2-9051-a8f7014ed184\" href=\"https://www.gov.uk/government/publications/flu-vaccination-leaflets-and-posters\">leaflets</a> published by Public Health England (PHE). <a data-hyperlink-id=\"32bcb792-4d3b-4523-ab28-a8f7014ed19f\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/451735/9407_PHE_Pregnancy_Flu_DL_leaflet_06b_web.pdf\">PHE</a> and the <a data-hyperlink-id=\"88d46469-bd1c-48db-9b51-a8f7014ed1a8\" href=\"http://www.medicinesinpregnancy.org/Medicine--pregnancy/Flu-vaccine/\">UK Teratology Information Service</a> have also produced patient leaflets on influenza vaccination in pregnancy.</li></ul><!-- end field 398903df-baf0-4bb9-a135-76057845cbaf --><!-- end item 689d104f-f313-43fc-b4f3-25f1fce6c415 -->","subChapters":[{"id":"c73a79cc-93e1-579e-8764-a5d11c8d90ea","slug":"basis-for-recommendation-c40","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 04f4d2f5-b91a-4132-976a-cead6b8d4236 --><h4>Basis for recommendation</h4><!-- end field 04f4d2f5-b91a-4132-976a-cead6b8d4236 -->","summary":null,"htmlStringContent":"<!-- begin item c40afe8d-9208-478c-8801-1d1c3e918c4f --><!-- begin field 52a2d5ad-1706-4cdc-9bdd-3fe36b3d869d --><p>These recommendations are based on the chapter <em>Influenza</em> in the Public Health England (PHE) document <em>Immunisation against infectious disease (the 'Green Book') </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-seasonal-influenza/references/\">PHE, 2019a</a>], and some are also pragmatic, based on what CKS considers to be good medical practice.</p><!-- end field 52a2d5ad-1706-4cdc-9bdd-3fe36b3d869d --><!-- end item c40afe8d-9208-478c-8801-1d1c3e918c4f -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}